Article Menu

Export Article

More by Authors Links

Article Data

  • Views 1967
  • Dowloads 128

Editorial

Open Access Special Issue

Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer

  • Tamás Kullmann1,*,

1Department of Oncoradiology, Petz Aladár Hospital, 9024 Győr, Hungary

DOI: 10.31083/j.jomh1807155 Vol.18,Issue 7,July 2022 pp.1-2

Published: 31 July 2022

(This article belongs to the Special Issue Therapy and prognosis of metastatic prostate cancer)

*Corresponding Author(s): Tamás Kullmann E-mail: kullmanndoki@hotmail.com

PDF (160.04 kB) View Full-text

Cite and Share

Tamás Kullmann. Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate Cancer. Journal of Men's Health. 2022. 18(7);1-2.

URL:

https://www.jomh.org/articles/10.31083/j.jomh1807155

References

[1] Sun X, Kour BD, Wang X, Hu X, Wang Y, Sugunakar VJ. In-sights into association between urolithiasis and prostate cancer. Journal of Men’s Health. 2021; 17: 52–61.

[2] Datta D, Aftabuddin M, Kundu R, Baid M, Das SK, Sarkar S, et al. A comprehensive mechanistic basis of prostate cancer ad-vancement & its personalized implementation-bridging the gap: present state and future prospect. Journal of Men’s Health. 2021; 17: 18–35.

[3] Lewis-Thames MW, Khan S, Hicks V, Drake BF. Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening program. Journal of Men’s Health. 2021; 17: 78–83.

[4] Porav-Hodade D, Balan D, Gherasim R, Vida OA, Todea-Moga C, Voidazan S, et al. Decrease in prostate cancer detection during COVID-19 pandemic. Journal of Men’s Health. 2021; 17: 151–155.

[5] Alkan A, Güç ZG, Gürbüz M, Özgün G, Değirmencioğlu S, Doğan M, et al. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate can-cer in geriatric (≥75) patients. Journal of Men’s Health. 2021; 17: 128–134.

[6] Yang X, Shan J, Zhang Q, Yuan Z, Xu H, Liu Z, et al. The diag-nostic value of a new formula combining age and prostate vol-ume in prostate cancer. Journal of Men’s Health. 2022; 18: 29.

[7] András S, Károly K, Adél A, Noémi K, Zsolt S, Tamás K. A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancer. Journal of Men’s Health. 2022; 18: 45.

[8] Tamás K, Károly K, Adél A, Noémi K, Ágnes H, Zsolt S. Op-timisation of second line antihormonal treatment for castration resistant metastatic prostate cancer. Journal of Men’s Health. 2022; 18: 93.

[9] Khader AA, Nsour E, Edwan TA. Prostatic signet-ring adeno-carcinoma: a case report. Journal of Men’s Health. 2022; 18: 90.

[10] Kullmann T, András S, Noémi K, Zsolt S. Neuroendocrine can-cer of the prostate. Two case reports. Journal of Men’s Health. 2022; 18: 065.

[11] Fang H, He L, He H, Wang X, Wang Y, Ge H, et al. The 100 most-cited articles in castration-resistant prostate cancer: a bib-liometric analysis. Journal of Men’s Health. 2022; 18: 3.

[12] Hurst R, Meader E, Gihawi A, Rallapalli G, Clark J, Kay GL, et al. Microbiomes of Urine and the Prostate are Linked to Hu-man Prostate Cancer Risk Groups. European Urology Oncology. 2022. (in press)


Submission Turnaround Time

Top